

North Central London

# Lipid Management: Medicines Optimisation Pathways

Developed by NCL Joint Formulary Committee & UCL Partners

Approval date: 24/08/2022

Review date: 24/08/2025

Updated Oct 2023: addition of bempedoic acid monotherapy

Not to be used for commercial or marketing purposes. Strictly for use within the NHS.




North Central London  
Joint Formulary Committee



# Contents

- Slide 3: Optimisation Pathway for Primary Prevention
- Slide 4: Optimisation Pathway for Secondary Prevention
- Slide 5: Statin Intensity Table
- Slide 6: Shared Decision-Making Resources
- Slide 7: Statin Intolerance Pathway
- Slide 8: Muscle Symptoms Pathway
- Slide 9: Abnormal Liver Function Test Pathway
- Slide 10: Lipid Clinic Contact Details & Links to Related Guidance
- Slide 11: Summary of lipid lowering options
- Slide 12: Supplementary Info: Inclisiran for secondary prevention
- Slide 13: Supplementary Info: Bempedoic acid for use in statin intolerance

# Optimisation Pathway for Primary Prevention




Optimal High Intensity statin for Primary Prevention  
(High intensity statins are substantially more effective at preventing cardiovascular events than low/medium intensity statins)

Atorvastatin	20mg
Rosuvastatin	10mg

\* If statin not tolerated, follow [statin intolerance pathway](#) and consider ezetimibe 10mg daily +/- [bempedoic acid](#) 180mg daily (or [bempedoic acid monotherapy if patient is intolerant to both statins and ezetimibe.](#))

Further information on management for patients with chronic kidney disease (CKD) is available in the [NHS AAC lipid management guidance](#)

# Optimisation Pathway for Secondary Prevention



**Optimal High Intensity Statin for secondary prevention**  
(High intensity statins are substantially more effective at preventing cardiovascular events than low/medium intensity statins)

Atorvastatin	80mg
--------------	------

Rosuvastatin	20mg
--------------	------

\* Dose may be limited if:

- eGFR<30ml/min – see [product license](#) or [NHS AAC lipid management guidance](#)
  - Drug interactions
  - Intolerance
  - Older age / frailty
- See [product license](#) or [NHS AAC lipid management guidance](#) for further information

\*\* See [statin intensity table](#)

\*\*\* Current [NICE Guidance](#) recommends a 40% reduction in non- HDL cholesterol

\*\*\*\* Measure uric acid and renal function

# Statin Intensity Table – NICE recommends Atorvastatin and Rosuvastatin as First Line

Approximate Reduction in LDL-C					
Statin dose mg/day	5	10	20	40	80
Pravastatin		20%	24%	29%	
Simvastatin		27%	32%	37%	42%
Atorvastatin		37%	43%	49%	55%
Rosuvastatin	38%	43%	48%	53%	
Atorvastatin + Ezetimibe 10mg		52%	54%	57%	61%

- Low/moderate intensity statins** will produce an LDL-C reduction of 20-30%
- Medium intensity statins** will produce an LDL-C reduction of 31-40%
- High intensity statins** will produce an LDL-C reduction above 40%
- Simvastatin 80mg** is not recommended due to risk of muscle toxicity

# Shared Decision-Making Resources

Benefits per 10,000 people taking statin for 5 years	Events avoided
Avoidance of major CVD events in patients with pre-existing CVD & a 2mmol/l reduction in LDL	1,000
Avoidance of major CVD events in patients with no pre-existing CVD & a 2mmol/l reduction in LDL	500

Adverse events per 10,000 people taking statin for 5 years	Adverse events
Myopathy	5
Haemorrhagic Strokes	5-10
Diabetes Cases	50-100

Shared decision-making resources:

- [BHF information on statins](#)
- [Heart UK: Information on statins](#)
- [NICE shared decision-making guide](#)

## Important considerations

- Most adverse events attributed to statins are no more common than placebo\*
- Consider food and drug interactions which may be contributing to adverse effects – see SPC \*
- Stopping statin therapy is associated with an increased risk of major CV events. It is important not to label patients as ‘statin intolerant’ without structured assessment
- If a person is not able to tolerate a high-intensity statin, aim to treat with the maximum tolerated dose
- A statin at any dose reduces CVD risk – consider annual review for patients not taking statins to review cardiovascular risk and interventions

\*(Collins et al systematic review, Lancet 2016)

## A structured approach to reported adverse effects of statins

1. Stop for 4-6 weeks.
2. If symptoms persist, they are unlikely to be due to statin
3. Restart and consider lower initial dose
4. If symptoms recur, consider trial with alternative statin
5. If symptoms persist, consider ezetimibe
6. Add in [bempedoic acid](#) if required for further lipid lowering as per NICE guidance
7. Bempedoic acid monotherapy can be prescribed for patients who are intolerant to statins **and** ezetimibe


Atorvastatin SmPC:

<https://www.medicines.org.uk/emc/product/5274/smpc#gref>

Rosuvastatin SmPC:

<https://www.medicines.org.uk/emc/product/4366/smpc#gref>


# Muscle Symptoms Pathway



**Detailed guidance:**  
<https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/08/Statintolerance-pathway-January-2022.pdf>



# Abnormal Liver Function Test (Transaminitis) Pathway



- Do not routinely exclude from statin therapy people who have liver transaminase levels that are raised but are less than 3 times the upper limit of normal.
- Most adults with fatty livers are likely to benefit from statins and this is not a contraindication.
- Check liver function at baseline, at 3 months and 12 months after initiation of statin therapy.

# Lipid Clinic Contact Details

Royal Free London NHS Foundation Trust	UCLH NHS Foundation Trust
Dr Devaki Nair Clinical Lead for Lipids & CVD Prevention Devaki.nair@nhs.net Tel: 020 7472 6694 Ext 33489 Clinical Nurse Specialist Tel: 0207 317 7723	Dr Catherine Lunken Department of Diabetes & Endocrinology 250 Euston Road, London NW1 2PG Catherine.lunken@nhs.net uclh.endocrinology@nhs.net Tel: 020 3447 9029

## Links to Related Guidance

Familial hypercholesterolaemia: <https://www.nice.org.uk/guidance/cg71>

Hypertriglyceridaemia guidance: [https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/2\\_Guidance\\_for\\_the\\_management\\_of\\_hypertriglyceridaemia.pdf](https://www.ncl-mon.nhs.uk/wp-content/uploads/Guidelines/2_Guidance_for_the_management_of_hypertriglyceridaemia.pdf)

NHS AAC National Guidance for Lipid Management for Primary and Secondary Prevention of CVD: <https://www.england.nhs.uk/aac/wp-content/uploads/sites/50/2020/04/Summary-of-national-guidance-for-lipid-management-for-primary-and-secondary-prevention-of-cardiovascular-disea.pdf>

## Summary of Lipid Lowering Therapies

Drug class	<u>NICE approved</u> Indication	Administration	LDL-lowering efficacy	CV outcomes evidence	Safety data
<b>Statins</b>	Primary prevention, Secondary prevention, Familial hypercholesterolaemia (FH)	Oral tablet given once daily	High intensity statins can lower LDL-C by 40% -55% (depending on agent and dose) <sup>1</sup>	Multiple outcome studies confirming CV outcomes benefit across a wide range of patient cohorts. For every 10,000 people treated for 5 years: - In secondary prevention (established CVD): 1,000 heart attacks, strokes or deaths avoided - NNT over 5 years = 10 - In primary prevention: 500 heart attacks, strokes or deaths avoided <sup>7</sup> - NNT over 5 years = 20	Long term safety data has been well established over 30 years  For every 10,000 people treated for 5 years: - 5 cases of myopathy - 5-10 haemorrhagic strokes - 50-100 new cases of diabetes <sup>7</sup>
<b>Ezetimibe</b>	Primary prevention, Secondary prevention and FH where statins are contraindicated, not tolerated or ineffective	Oral tablet given once daily	An additional LDL-C reduction of 24% in combination with statins <sup>2</sup>	Two CV outcomes studies in secondary prevention on top of statins – demonstrating NNTs between 42-50 for preventing major cardiovascular event over 3.5-7 years. <sup>8,9</sup> For every 10,000 people with CVD treated for 5 years: - Approximately 200 major CV events avoided	Long term safety data has been well-established over 15 years
<b>PCSK9i (Alirocumab/ Evolocumab)</b>	Secondary prevention and FH in patients who meet eligibility criteria	Self-administered S/C injection every two weeks	An additional LDL-C reduction of approximately 50% (range 25-70%) alone or in combination with statins or ezetimibe. <sup>3,4</sup>	Two CV outcomes studies in secondary prevention on top of statins <sup>10,11</sup> For every 10,000 people treated for 2 years - Approximately 150 major CV events avoided - NNT over 2 years = 65 <sup>12</sup>	Safety data has been established over 5 years
<b>Bempedoic acid</b>	For use where statins are not tolerated in combination with ezetimibe, if ezetimibe alone does not control LDL-C well enough	Oral tablet given once daily	An additional LDL-C reduction of approximately 28% (range 22-33%) when combined with ezetimibe <sup>5</sup>	No CV outcomes data. On-going studies due to report in 2022.	Short term safety data from trials of up to 2 years.
<b>Inclisiran</b>	Secondary prevention in patients who meet eligibility criteria	S/C injection administered by a healthcare professional every six months, once stabilised	An additional LDL-C reduction of approximately 50% (range 48-52%) alone or in combination with statins or ezetimibe <sup>6</sup>	No CV outcomes data. On-going studies due to report in 2026.	Short term safety data from trials of up to 2 years.

### References:

1. NICE CG181 2014 <https://www.nice.org.uk/guidance/cg181/chapter/1-recommendations>; 2. NICE TA385 2016 <https://www.nice.org.uk/guidance/ta385>; 3. NICE TA393 2016. <https://www.nice.org.uk/guidance/ta394> 4. NICE TA394 2016. <https://www.nice.org.uk/guidance/ta394> 5. NICE TA694 2021. <https://www.nice.org.uk/guidance/ta694> 6. NICE TA733 2021. <https://www.nice.org.uk/guidance/ta733> 7. Collins et al. 2016. Lancet 2016; 388: 2532-61. 8. Cannon CP et al. 2015. N Engl J Med 2015; 372:2387-2397. 9. Cannon CP et al. 2020. N Engl J Med 2020; 382:9-19. 10. Sabatine et al. 2017. N Engl J Med 2017; 376:1713-1723. 11. Schwarz GG et al. 2018. N Engl J Med 2018; 379:2097-2107. 12. Can Fam Physician. 2018 Sep; 64(9): 669.

# Inclisiran for secondary prevention

- Inclisiran is indicated only for patients:
  - With established CVD
  - On optimal oral lipid lowering therapy including high intensity statins where tolerated
  - Where LDL-C remains  $\geq 2.6$ mmol/L
- Inclisiran lowers LDL-C by approx. 50%, but there are currently no long term CVD outcome data or safety data and this should be taken into account when making a shared decision with the patient about appropriate treatment choices
- Inclisiran is administered at a dose of 284mg by subcutaneous injection
- It should be given at month 0 (initiation), month 3, month 9 and then every 6 months thereafter.
  - If a planned dose is missed by more than 3 months, a new dosing schedule should be started – inclisiran should be administered initially, again at 3 months, followed by every 6 months.
  - It should be administered by a healthcare professional into the abdomen; alternative injection sites include the upper arm or thigh.
- The only adverse reactions associated with inclisiran reported to date are injection site reactions (8.2%)
- More information on inclisiran can be found at:  
<https://www.medicines.org.uk/emc/product/12039/smpc#gref>

# Bempedoic acid for use in statin intolerance

- Bempedoic acid with ezetimibe is recommended as an option for treating primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia as an adjunct to diet in adults. It is recommended only if:
  - statins are contraindicated or not tolerated and
  - ezetimibe alone does not control low-density lipoprotein cholesterol well enough
- Bempedoic acid lowers LDL-C by an additional 28% (range 22-33%) when combined with ezetimibe. There are currently no long term CVD outcome data or safety data and this should be taken into account when making a shared decision with the patient about appropriate treatment choices
- The recommended dose of bempedoic acid is one film-coated tablet of 180 mg taken once daily
- Bempedoic acid with ezetimibe can be prescribed as separate tablets or a fixed-dose combination
- Bempedoic acid monotherapy can be considered if both statins and ezetimibe are not tolerated
- Bempedoic acid was associated with a slightly increased risk of tendon rupture, involving the biceps tendon, rotator cuff, or Achilles tendon. Other more commonly reported adverse events in clinical trials were upper respiratory tract infection, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anaemia, and elevated liver enzymes
- More information on bempedoic acid can be found at: <https://www.medicines.org.uk/emc/product/11743/smpc#gref>